AbbVie (NYSE:ABBV) Shares Up 1.6% – What’s Next?

AbbVie Inc. (NYSE:ABBV) shares traded up 1.6% during trading on Thursday . The stock traded as high as $255.31 and last traded at $254.9960. Approximately 4,392,954 shares traded hands during mid-day trading, a decline of 34% from the average daily volume of 6,649,387 shares. The stock had previously closed at $250.91.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported positive Phase 3 LUNA results for atogepant in the prevention of menstrual migraine. The treatment met the study’s primary goal and showed efficacy and safety, potentially supporting an additional growth opportunity for the migraine portfolio. AbbVie’s migraine treatment meets late-stage study goal
• Positive Sentiment: The LUNA data reinforces AbbVie’s position in migraine care and could expand the commercial potential of atogepant, adding another source of growth as Humira sales decline. AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results
• Positive Sentiment: HSBC raised its AbbVie price target to $315 from $300 while maintaining a Buy rating, signaling increased confidence in the company’s earnings outlook and pipeline. HSBC Adjusts Price Target on AbbVie
• Positive Sentiment: Skyrizi and Rinvoq continue to drive immunology growth, while new indications, partnerships and acquisitions—including the Apogee Therapeutics transaction—are intended to build AbbVie’s next wave of products. AbbVie’s Immunology Franchise
• Positive Sentiment: AbbVie declared a quarterly cash dividend of $1.73 per share, supporting the stock’s income appeal and indicating continued confidence in cash generation. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: Analyst commentary highlights AbbVie’s successful transition away from Humira toward newer immunology products, but also raises questions about whether future growth is becoming too dependent on Skyrizi and Rinvoq. AbbVie vs. Novo Nordisk
• Negative Sentiment: The FDA issued a complete response letter for the fast-acting neurotoxin trenibotE, delaying or complicating a potential product launch and adding regulatory risk to AbbVie’s aesthetics pipeline. FDA Issues Complete Response Letter for TrenibotE

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. JPMorgan Chase & Co. boosted their price target on AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Wells Fargo & Company upped their price objective on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. Canaccord Genuity Group increased their target price on shares of AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Royal Bank Of Canada raised their target price on shares of AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research note on Friday, July 10th. Finally, Guggenheim boosted their price target on shares of AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $276.64.

AbbVie Stock Up 1.6%

The company has a 50 day moving average of $254.66 and a two-hundred day moving average of $230.55. The firm has a market cap of $450.52 billion, a P/E ratio of 72.03, a PEG ratio of 1.13 and a beta of 0.29.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts expect that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s payout ratio is 195.48%.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Institutional Trading of AbbVie

Several institutional investors and hedge funds have recently bought and sold shares of ABBV. Rench Wealth Management Inc. purchased a new stake in AbbVie during the second quarter valued at about $215,000. Miramontes Capital LLC lifted its position in shares of AbbVie by 2.9% in the 2nd quarter. Miramontes Capital LLC now owns 3,668 shares of the company’s stock valued at $923,000 after acquiring an additional 104 shares in the last quarter. Capstone Financial Advisors Inc. boosted its stake in AbbVie by 1.4% in the 2nd quarter. Capstone Financial Advisors Inc. now owns 3,914 shares of the company’s stock worth $985,000 after purchasing an additional 55 shares during the period. Tortoise Investment Management LLC grew its position in AbbVie by 7.6% during the 2nd quarter. Tortoise Investment Management LLC now owns 1,128 shares of the company’s stock worth $284,000 after purchasing an additional 80 shares in the last quarter. Finally, Community Bank of Raymore raised its stake in AbbVie by 2.0% during the 2nd quarter. Community Bank of Raymore now owns 12,673 shares of the company’s stock valued at $3,189,000 after purchasing an additional 250 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.